These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21616117)

  • 21. Reducing the economic burden of HPV-related diseases.
    Mayeaux EJ
    J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S2-7. PubMed ID: 18463361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
    Ginindza TG; Sartorius B; Dlamini X; Östensson E
    PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus infection: epidemiology and pathophysiology.
    Steben M; Duarte-Franco E
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S2-5. PubMed ID: 17938014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the significance of the HPV epidemic?
    Anorlu RI
    Can J Urol; 2008 Feb; 15(1):3860-5. PubMed ID: 18304395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
    Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
    Insinga RP; Ye X; Singhal PK; Carides GW
    Gynecol Oncol; 2008 Nov; 111(2):188-96. PubMed ID: 18757080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention strategies against human papillomavirus in males.
    Garland SM
    Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic burden of HPV9-related diseases: a real-world cost analysis from Italy.
    Mennini FS; Fabiano G; Favato G; Sciattella P; Bonanni P; Pinto C; Marcellusi A
    Eur J Health Econ; 2019 Aug; 20(6):829-840. PubMed ID: 30900047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural history and epidemiology of HPV infection and cervical cancer.
    Castellsagué X
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S4-7. PubMed ID: 18760711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003.
    Ryerson AB; Peters ES; Coughlin SS; Chen VW; Gillison ML; Reichman ME; Wu X; Chaturvedi AK; Kawaoka K
    Cancer; 2008 Nov; 113(10 Suppl):2901-9. PubMed ID: 18980273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods.
    Watson M; Saraiya M; Ahmed F; Cardinez CJ; Reichman ME; Weir HK; Richards TB
    Cancer; 2008 Nov; 113(10 Suppl):2841-54. PubMed ID: 18980203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The costs of treating vaginal and vulval cancer in England (2009-2015).
    Stephens S; Chatterjee A; Coles V; Crawford R
    BMC Public Health; 2020 Apr; 20(1):453. PubMed ID: 32252711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus: often harmless but in some cases carcinogenic.
    Prescrire Int; 2007 Jun; 16(89):115-9. PubMed ID: 17585425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolution of HPV-related anogenital cancers reported in Quebec - incidence rates and survival probabilities.
    Louchini R; Goggin P; Steben M
    Chronic Dis Can; 2008; 28(3):99-106. PubMed ID: 18341764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Invasive cervical cancer treatment costs in France].
    Arveux P; Bénard S; Bouée S; Lafuma A; Martin L; Cravello L; Rémy V; Breugelmans JG
    Bull Cancer; 2007 Feb; 94(2):219-24. PubMed ID: 17337390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies against human papillomavirus infection and cervical cancer.
    Jung WW; Chun T; Sul D; Hwang KW; Kang HS; Lee DJ; Han IK
    J Microbiol; 2004 Dec; 42(4):255-66. PubMed ID: 15650698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.